Skip to main content

NUEVAS FUNCIONES Y MECANISMOS DE ENZIMAS BACTERIANOS DE LA SUPERFAMILIA ARQUEO/EUCARIOTA DE PRIMASAS

BFU2017-83900-P

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Loop of the TPR1 Subdomain of Phi29 DNA Polymerase Plays a Pivotal Role in Primer-Terminus Stabilization at the Polymerization Active Site

  • Prado, Alicia del
  • Santos, Eugenia
  • Lázaro, José M.
  • Salas, Margarita
  • Vega, Miguel de
© The Author(s)., Bacteriophage Phi29 DNA polymerase belongs to the protein-primed subgroup of family B DNA polymerases that use a terminal protein (TP) as a primer to initiate genome replication. The resolution of the crystallographic structure showed that it consists of an N-terminal domain with the exonuclease activity and a C-terminal polymerization domain. It also has two subdomains specific of the protein-primed DNA polymerases; the TP Regions 1 (TPR1) that interacts with TP and DNA, and 2 (TPR2), that couples both processivity and strand displacement to the enzyme. The superimposition of the structures of the apo polymerase and the polymerase in the polymerase/TP heterodimer shows that the structural changes are restricted almost to the TPR1 loop (residues 304–314). In order to study the role of this loop in binding the DNA and the TP, we changed the residues Arg306, Arg308, Phe309, Tyr310, and Lys311 into alanine, and also made the deletion mutant Δ6 lacking residues Arg306–Lys311. The results show a defective TP binding capacity in mutants R306A, F309A, Y310A, and Δ6. The additional impaired primer-terminus stabilization at the polymerization active site in mutants Y310A and Δ6 allows us to propose a role for the Phi29 DNA polymerase TPR1 loop in the proper positioning of the DNA and TP-priming 3’-OH termini at the preinsertion site of the polymerase to enable efficient initiation and further elongation steps during Phi29 TP-DNA replication., Spanish Ministry of Science, Innovation and Universities grant BFU2014-52656-P and PGC2018-093726-B-100 to M.S., and BFU2017-83900-P AEI/FEDER UE to M.V., and by institutional grants from Fundación Ramón Areces and Banco de Santander to the Centro de Biología Molecular Severo Ochoa., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function

  • Michel, Maurice
  • Benitez-Buelga, Carlos
  • Calvo, Patricia A.
  • Hanna, Bishoy M. F.
  • Mortusewicz, Oliver
  • Masuyer, Geoffrey
  • Davies, Jonathan
  • Wallner, Olov
  • Sanjiv, Kumar
  • Albers, Julian J.
  • Castañeda-Zegarra, Sergio
  • Jemth, Ann-Sofie
  • Visnes, Torkild
  • Sastre-Perona, Ana
  • Danda, Akhilesh N.
  • Homan, Evert J.
  • Marimuthu, Karthick
  • Zhenjun, Zhao
  • Chi, Celestine N.
  • Sarno, Antonio
  • Wiita, Elisée
  • Nicolai, Catharina von
  • Komor, Anna J.
  • Rajagopal, Varshni
  • Müller, Sarah
  • Hank, Emily C.
  • Varga, Marek
  • Scaletti, Emma R.
  • Pandey, Monica
  • Karsten, Stella
  • Haslene-Hox, Hanne
  • Loevenich, Simon
  • Marttila, Petra
  • Rasti, Azita
  • Mamonov, Kirill
  • Ortis, Florian
  • Schömberg, Fritz
  • Loseva, Olga
  • Stewart, Josephine
  • D’Arcy-Evans, Nicholas
  • Koolmeister, Tobias
  • Henriksson, Martin
  • Michel, Dana
  • Ory, Ana de
  • Acero, Lucia
  • Calvete, Oriol
  • Scobie, Martin
  • Hertweck, Christian
  • Vilotijevic, Ivan
  • Kalderén, Christina
  • Osorio, Ana
  • Perona Abellón, Rosario
  • Stolz, Alexandra
  • Stenmark, Pål
  • Warpman Berglund, Ulrika
  • Vega, Miguel de
  • Helleday, Thomas
Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. https://www.sciencemag.org/about/science-licenses-journal-article-reuse This is an article distributed under the terms of the Science Journals Default License., Oxidative DNA damage is recognized by 8-oxoguanine (8-oxoG) DNA glycosylase 1 (OGG1), which excises 8-oxoG, leaving a substrate for apurinic endonuclease 1 (APE1) and initiating repair. Here, we describe a small molecule (TH10785) that interacts with the phenylalanine-319 and glycine-42 amino acids of OGG1, increases the enzyme activity 10-fold, and generates a previously undescribed β,δ-lyase enzymatic function. TH10785 controls the catalytic activity mediated by a nitrogen base within its molecular structure. In cells, TH10785 increases OGG1 recruitment to and repair of oxidative DNA damage. This alters the repair process, which no longer requires APE1 but instead is dependent on polynucleotide kinase phosphatase (PNKP1) activity. The increased repair of oxidative DNA lesions with a small molecule may have therapeutic applications in various diseases and aging., This work was supported by European Research Council grant TAROX-695376 (T.H.); Swedish Research Council grant 2015-00162 (T.H.); Swedish Research Council grant 2018-03406 (P.S.); Ministry of Science and Innovation, Spain/State Research Agency, Spain/10.13039/501.100011033 and “ERDF A way to make Europe” grant BFU2017-83900-P (M.d.V.); Crafoord Foundation grant 20190532 (P.S.); an Alfred Österlund Foundation grant (P.S.); a Swedish Pain Relief Foundation grant (T.H.); Swedish Cancer Society grant CAN2018/0658 (T.H.); Swedish Cancer Society grant CAN 2017/716 (P.S.); a Torsten and Ragnar Söderberg foundation grant (T.H.); Dr. Åke-Olsson Foundation for Hematological Research grant 2020-00306 (M.M.); the Thomas Helleday Foundation for medical research postdoctoral stipends (M.M. and C.B.-B.); the NTNU Enabling Technology Programme on Biotechnology to Valentyn Oksenych (S.C.-Z.); EMBO Short-Term Fellowship 9005 (S.C.-Z.); a FEBS Short-Term Fellowship (S.C.-Z.); SSI Grants for Scandinavian Exchange (S.C.-Z.); German Research Foundation (DFG) 239748522 (A.J.K. and C.H.); Sonderforschungsbereich (SFB) 1127 (A.J.K. and C.H.); The Leibniz Award (C.H.); Norwegian Research Council grant 303369 (T.V.); Karolinska Institutet Research Foundation grant 2020-02186 (M.M.); a Lars Hiertas Minne Stiftelse grant (M.M.); and Asociacion Española Contra Cancer grant Postdoctoral AECC 2020, Nº POSTD20042BENI (C.B.-B.). This study was funded by “Instituto de Salud Carlos III CP19/00063 and PI20/00329” and cofunded by European Social Fund “Investigating in your future” and “European Regional Development Fund” (A.S.-P.). CNIO studies are partially funded by Instituto de Salud Carlos III, project reference PI19/00640, and cofounded by the European Regional Development Fund (ERDF), “A way to make Europe” (A.O.). This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 875510 (M.M., E.J.H., E.W., and A.St.). This work received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 722729 (T.H. and B.M.F.H.)., Peer reviewed